Tirzepatide: A Complete Guide to Mounjaro, Zepbound, Results, and Cost

What Tirzepatide Is and How It Works

Tirzepatide is a single molecule that activates two different gut hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Semaglutide and older GLP-1 medications only activate the GLP-1 receptor. The addition of GIP activation is what makes tirzepatide distinct, producing stronger effects on insulin sensitivity, appetite, and how your body processes fat.

In practical terms, the dual action means tirzepatide tends to reduce appetite more aggressively, improve blood sugar faster, and produce greater total weight loss than single-receptor GLP-1 drugs. It is delivered as a once-weekly injection and is titrated slowly over several months to manage side effects. Our guide on how tirzepatide compares to Ozempic breaks down the receptor biology in plain language, and our complete tirzepatide guide covers the pharmacology in depth.

Mounjaro vs Zepbound: Two Products, Same Molecule

Tirzepatide is sold under two brand names, both made by Eli Lilly. The active ingredient is identical, the dosing schedule is identical, and the pens are identical. What differs is FDA approval, insurance coverage, and list price.

Mounjaro is typically prescribed when the patient has a type 2 diabetes diagnosis, since insurance is more likely to cover it on that indication. Zepbound is the preferred prescription for weight management and is the only tirzepatide product approved for obstructive sleep apnea in adults with obesity, a 2024 approval that unlocked Medicare coverage for many patients. For a deeper breakdown of the practical differences, see our Zepbound vs Mounjaro comparison and our full Zepbound overview.

How Much Weight You Can Lose

The SURMOUNT trials set the benchmark for what tirzepatide can deliver. In SURMOUNT-1, participants without diabetes on the 15 mg weekly dose lost an average of 22.5% of their body weight over 72 weeks, compared to 2.4% on placebo. Participants on the 10 mg dose lost 21.4%, and those on 5 mg lost 16%. For someone starting at 220 pounds, the highest dose produced an average loss of about 49 pounds.

The head-to-head SURMOUNT-5 trial published in 2025 directly compared tirzepatide to semaglutide and showed tirzepatide produced roughly 47% more weight loss over 72 weeks. For diabetes patients, the SURPASS trials showed A1C reductions of 1.9 to 2.3 percentage points at higher doses, alongside meaningful weight loss.

Results vary widely by starting BMI, dose, and adherence. Our full breakdown of medications that help you lose 15 to 22% of body weight puts tirzepatide's numbers in context, and if your loss stalls, the Mounjaro weight loss stall guide walks through what to check. As with all GLP-1s, protein intake and resistance training are the two biggest determinants of whether you lose primarily fat or a mix of fat and muscle.

Side Effects and Safety

Tirzepatide's side effect profile is similar to semaglutide's, with gastrointestinal issues leading the list. Most symptoms appear during dose increases and fade as your body adjusts.

Serious but uncommon side effects include pancreatitis, gallbladder disease, and severe gastroparesis. Tirzepatide carries the same boxed warning as semaglutide for thyroid C-cell tumors, so it is not recommended for patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. For the full list of what to watch for and how to manage the common issues, see our Mounjaro side effects overview and our guide to sulfur burps on tirzepatide.

Rapid weight loss can also bring cosmetic changes like facial volume loss and muscle loss if protein intake and strength training are neglected.

Cost and Insurance Coverage

Tirzepatide pricing changed significantly in 2024 and 2025 when Eli Lilly launched LillyDirect, a direct-to-patient channel offering Zepbound vials (not pens) at reduced cash prices. The result is a wider range of options than almost any other prescription drug.

With commercial insurance, most patients pay between $25 and $550 per month depending on plan and prior authorization. Medicare began covering Zepbound in 2024 for patients with obstructive sleep apnea, and coverage for obesity more broadly remains limited. Without insurance, list prices run around $1,086 for Mounjaro pens and the same for Zepbound pens, while LillyDirect vials start at roughly $349 to $499 depending on dose. Telehealth compounding options that previously offered tirzepatide have largely pulled back after the FDA's shortage resolution, so compounded tirzepatide is harder to access than compounded semaglutide in 2026.

Our 2026 GLP-1 cost guide tracks current pricing across channels, and the insurance coverage guide covers what plans are approving this year. For most patients, the fastest way to understand what they will actually pay is to start an eligibility assessment.